Bron-Newcavac-SETM, an effective, long-lasting vaccine to control Newcastle disease, infectious bronchitis and Salmonella enteritidis - a serious threat to the poultry industry and human health has been introduced Monday (Nov 5) by Merck Animal Health.
"Salmonella is one of the most common food-borne, disease-causing bacteria and can pose significant risks to humans. Given the potential health threat the bacteria poses, commercial egg-laying operators are keenly aware of how vital it is to have a strong, FDA-compliant Salmonella enteritidis control programme in place," says Charles Broussard, D.V.M, MAM, Merck Animal Health.
In addition to controlling Salmonella enteritidis, Bron-Newcavac-SE controls the respiratory pathogens that cause Newcastle disease and infectious bronchitis when administered to chickens 10 weeks of age or older, as well as supports strong flock uniformity. Bron-Newcavac-SE is also a strong complement to the company's existing portfolio of innovative poultry health solutions, which include products to address intestinal health, respiratory protection and dynamic immunity.
"We know the impact of Salmonella enteritidis, Newcastle disease and infectious bronchitis, as well as a multitude of other health issues, can be devastating for a poultry producer," says Broussard. "That's why we are committed to providing our customers with the products, resources and support they need to help protect our food supply, meet regulatory guidelines and be successful in an ever-changing industry.
Merck Animal Health, known as MSD Animal Health outside the US and Canada, is the global animal health business unit of Merck. Merck Animal Health offers veterinarians, farmers, pet owners and government's one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services.
